Latest Advances in Lung Cancer Research

A major Australian-Canadian lung cancer screening study found that 73% of high-risk participants had incidental findings during baseline CT scans, with 10% requiring clinical follow-up, highlighting significant inconsistencies in how these findings are reported to doctors and raising important questions about standardization as Australia prepares to launch its national screening program in 2025.

Chest CT scans used for lung cancer screening can do more than just find early lung cancer. These scans can also detect heart problems and early emphysema, offering a three-in-one health check for people at risk.

Early detection of incidental lung nodules can lead to timely treatment and improved survival rates for lung cancer patients.

Scientists develop a groundbreaking urine test that detects “zombie” cell proteins, enabling early detection of lung cancer and potentially improving patient outcomes and prognosis.

UCLA researchers received a $6 million grant to refine a liquid biopsy blood test for early, accurate lung cancer detection and treatment guidance.

Researchers developed a test detecting proteins in blood that indicate lung cancer spread, promising for early metastasis detection and treatment guidance.

Rare EGFR exon insertions in lung cancer allow targeted therapies, but resistance develops; new drugs help.

Biomarker testing decisions for lung cancer vary by type of clinician. Fewer community oncology clinicians use biomarker testing.

Liquid biopsy simpler sampling: Liquid biopsies are easier on patients, yield faster results and cost less than tissue biopsies.

Future of liquid biopsy: Analysis of tumours using biomarkers in blood is beginning to transform cancer diagnosis.

Study defines SCLC subtypes. Study provides a transformative new system to define four major groups of small-cell lung cancer.

FDA approves new liquid biopsy tests using NGS to detect tumor DNA, aiding targeted cancer therapy selection.